ATE442387T1 - Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung - Google Patents

Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung

Info

Publication number: ATE442387T1
Authority: AT; Austria
Prior art keywords: interleukin; cell receptor; following infection; progression; aids
Prior art date: 2001-05-18

Application number

AT02730429T

Other languages

English (en)

Inventor

John Marchalonis

Ronald Watson

Original Assignee

Univ Arizona

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-18

Filing date

2002-05-17

Publication date

2009-09-15

2002-05-17 Application filed by Univ Arizona filed Critical Univ Arizona

2009-09-15 Application granted granted Critical

2009-09-15 Publication of ATE442387T1 publication Critical patent/ATE442387T1/de

Links

108091008874 T cell receptors Proteins 0.000 title abstract 3
102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 3
239000012634 fragment Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
208000015181 infectious disease Diseases 0.000 abstract 3
238000010171 animal model Methods 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
208000010648 susceptibility to HIV infection Diseases 0.000 abstract 2
XMVZMBGFIOQONW-GARJFASQSA-N Cys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)C(=O)O XMVZMBGFIOQONW-GARJFASQSA-N 0.000 abstract 1
HRGGKHFHRSFSDE-CIUDSAMLSA-N His-Asn-Ser Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N HRGGKHFHRSFSDE-CIUDSAMLSA-N 0.000 abstract 1
ZLFNNVATRMCAKN-ZKWXMUAHSA-N Ile-Ser-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZLFNNVATRMCAKN-ZKWXMUAHSA-N 0.000 abstract 1
102000008070 Interferon-gamma Human genes 0.000 abstract 1
108010074328 Interferon-gamma Proteins 0.000 abstract 1
102000003814 Interleukin-10 Human genes 0.000 abstract 1
108090000174 Interleukin-10 Proteins 0.000 abstract 1
102000000588 Interleukin-2 Human genes 0.000 abstract 1
108010002350 Interleukin-2 Proteins 0.000 abstract 1
102000000743 Interleukin-5 Human genes 0.000 abstract 1
108010002616 Interleukin-5 Proteins 0.000 abstract 1
102000004889 Interleukin-6 Human genes 0.000 abstract 1
108090001005 Interleukin-6 Proteins 0.000 abstract 1
TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 abstract 1
MAXILRZVORNXBE-PMVMPFDFSA-N Leu-Phe-Trp Chemical compound C([C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 MAXILRZVORNXBE-PMVMPFDFSA-N 0.000 abstract 1
HKIUVWMZYFBIHG-KKUMJFAQSA-N Tyr-Arg-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O HKIUVWMZYFBIHG-KKUMJFAQSA-N 0.000 abstract 1
239000000539 dimer Substances 0.000 abstract 1
108010020688 glycylhistidine Proteins 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
229940027941 immunoglobulin g Drugs 0.000 abstract 1
229960003130 interferon gamma Drugs 0.000 abstract 1
229940076144 interleukin-10 Drugs 0.000 abstract 1
229940100601 interleukin-6 Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000009885 systemic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Confectionery (AREA)

AT02730429T 2001-05-18 2002-05-17 Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung ATE442387T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0112126.8A GB0112126D0 (en)	2001-05-18	2001-05-18	Composition
PCT/GB2002/002323 WO2002094860A2 (en)	2001-05-18	2002-05-17	Dimerized t-cell receptor fragment, its compositions and use

Publications (1)

Publication Number	Publication Date
ATE442387T1 true ATE442387T1 (de)	2009-09-15

Family

ID=9914850

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02730429T ATE442387T1 (de)	2001-05-18	2002-05-17	Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung

Country Status (7)

Country	Link
US (1)	US7998926B2 (de)
EP (1)	EP1389219B1 (de)
AT (1)	ATE442387T1 (de)
AU (1)	AU2002302751A1 (de)
DE (1)	DE60233654D1 (de)
GB (1)	GB0112126D0 (de)
WO (1)	WO2002094860A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7323174B1 (en) *	2000-06-12	2008-01-29	Arizona Board Of Regents On Behalf Of The University Of Arizona	Modulation of immune response and methods based thereon
US8034773B2 (en) *	2004-02-05	2011-10-11	Arizona Biomedical Research Commission	Immunostimulatory compositions and uses thereof
JP5060284B2 (ja)	2004-03-30	2012-10-31	アンスティテュ・グスターブ・ルシ	ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列
EP1755635A4 (de) *	2004-05-27	2011-04-06	Novozymes Biopharma Au Ltd	Behandlung von entzündlicher atemwegserkrankung
US8178649B2 (en) *	2004-12-07	2012-05-15	Arizona Biomedical Research Commission	Immunostimulatory compositions and uses thereof
US7811995B2 (en) *	2006-12-13	2010-10-12	Susavion Biosciences, Inc.	Therapeutic and diagnostic peptides
US8496942B2 (en) *	2006-12-13	2013-07-30	Susavion Biosciences, Inc.	Therapeutic peptides and uses thereof
JP6740250B2 (ja)	2015-04-27	2020-08-12	スサヴィオンバイオサイエンシーズインコーポレイテッド	がんおよび持続性ウイルス感染を処置するための組成物および方法
CA3095757A1 (en)	2018-04-06	2019-10-10	The Regents Of The University Of California	Methods of treating glioblastomas
CA3096202A1 (en)	2018-04-06	2019-10-10	The Regents Of The University Of California	Methods of treating egfrviii expressing glioblastomas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8205892D0 (sv)	1982-10-18	1982-10-18	Bror Morein	Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv)	1984-11-01	1984-11-01	Bror Morein	Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ATE71303T1 (de)	1986-01-14	1992-01-15	Nederlanden Staat	Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en)	1986-04-15	1989-02-21	Ribi Immunochem Research Inc.	Immunological lipid emulsion adjuvant
WO1991010736A2 (en) *	1990-01-19	1991-07-25	Dana Farber Cancer Institute	CLONING AND CHARACTERIZATION OF THE CD3θ SUBUNIT
WO1992001715A1 (en) *	1990-07-19	1992-02-06	The Board Of Trustees Of The Leland Stanford Junior University	Soluble cell-surface dimeric proteins
EP0804561B1 (de)	1993-02-12	2009-12-30	The Board Of Trustees Of The Leland Stanford Junior University	Regulierte transkription von zielgerichteten genen und andere biologische ereignisse
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
WO1996021028A2 (en) *	1995-01-03	1996-07-11	Procept, Inc.	Soluble heterodimeric t cell receptors and their antibodies
US6150337A (en)	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5714577A (en) *	1996-01-26	1998-02-03	University Of Pittsburgh	Antimicrobial peptides
NZ331688A (en) *	1996-03-28	2000-02-28	Univ Johns Hopkins	Soluble divalent and multivalent heterodimeric analogs of proteins
US5962319A (en)	1997-05-19	1999-10-05	Bml, Inc.	Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
US5911990A (en) *	1996-08-13	1999-06-15	Arizona Board Of Regents On Behalf Of The University Of Arizona	T-cell receptor peptides and methods for preventing the progression to AIDS in an animal model
IL119938A (en) *	1996-12-30	2005-08-31	Yissum Res Dev Co	Peptides capable of eliciting protective immunity against toxic shock induced by pyrogenic exotoxins or of antagonizing toxin-mediated activation of t cells
US7323174B1 (en) *	2000-06-12	2008-01-29	Arizona Board Of Regents On Behalf Of The University Of Arizona	Modulation of immune response and methods based thereon

2001
- 2001-05-18 GB GBGB0112126.8A patent/GB0112126D0/en not_active Ceased
2002
- 2002-05-17 WO PCT/GB2002/002323 patent/WO2002094860A2/en not_active Ceased
- 2002-05-17 US US10/478,194 patent/US7998926B2/en active Active
- 2002-05-17 AU AU2002302751A patent/AU2002302751A1/en not_active Abandoned
- 2002-05-17 AT AT02730429T patent/ATE442387T1/de not_active IP Right Cessation
- 2002-05-17 EP EP02730429A patent/EP1389219B1/de not_active Expired - Lifetime
- 2002-05-17 DE DE60233654T patent/DE60233654D1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU2002302751A1 (en)	2002-12-03
US20040248192A1 (en)	2004-12-09
US7998926B2 (en)	2011-08-16
DE60233654D1 (de)	2009-10-22
EP1389219B1 (de)	2009-09-09
WO2002094860A3 (en)	2003-06-26
GB0112126D0 (en)	2001-07-11
EP1389219A2 (de)	2004-02-18
WO2002094860A2 (en)	2002-11-28

Legal Events

Date	Code	Title	Description
2010-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
RU2010116278A (ru)	2011-11-10	Модифицированная константная область антитела
NL300013I1 (nl)	2000-10-02	Nieuwe protein met TNF-remmende werking en hun ber
PL363071A1 (pl)	2004-11-15	Sposoby i kompozycje dla zmniejszenia replikacji HIV-1
AU6285694A (en)	1994-10-11	Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine
JP2004518624A5 (de)	2008-11-06
ATE442387T1 (de)	2009-09-15	Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
WO2006034334A3 (en)	2006-09-14	Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
WO2006023665A3 (en)	2006-08-03	Il-1 antagonist formulations
YU394A (sh)	1997-07-31	Novi peptidi koji deluju kao antagonisti opijatskih receptora i postupci za njihovu izradu
KR980002066A (ko)	1998-03-30	변이형 인간 성장호르몬 및 그의 용도
ATE256185T1 (de)	2003-12-15	T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
DK1447414T3 (da)	2007-09-10	Antagonistpeptider af carcinoembronisk antigen (CEA)
ES2123556T3 (es)	1999-01-16	Peptidos de tipo bradiquinina.
TR200003498T2 (tr)	2001-10-22	Amino asit sekansından oluşan bir polipetit, bunun aşıları ve kullanımları
ES2180781T3 (es)	2003-02-16	Nuevos ligandos del receptor opiaceo mu: agonistas y antagonistas.
CA2397267A1 (en)	2001-08-02	Peptide fragments and uses thereof as type-1 interferon antagonist
EP1578772A4 (de)	2007-05-09	Cytokine und cytokinrezeptoren mit reduzierter immunogenität
EP1908781A3 (de)	2008-04-16	Modulation der Immunreaktion und darauf basierende Verfahren
WO2001051512A3 (en)	2002-03-14	Human and parasite orphan receptor proteins
ATE420890T1 (de)	2009-01-15	Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide
IL154777A0 (en)	2003-10-31	Il-6 receptor/il-6 chimera in huntington's disease
EP0717752A4 (de)	1997-08-20	Therapeitische inhaltsstoffe
WO2005072766A3 (en)	2006-05-11	Peptides that bind to hsp90 proteins
EP1372691A4 (de)	2005-11-09	Mucinpeptid mit immunstärkenden eigenschaften
Hamaoka	1985	T-cell-replacing factor and its acceptor site on B cells: molecular properties and immunogenetic aspects